HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Werewolf Therapeutics Inc (HOWL) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Growth (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | D (1.3) | C+ (2.7) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-08-04 | C+ (2.7) | D (1.3) | C+ (2.7) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-08-03 | C+ (2.7) | C- (2.0) | C- (2.0) | C (2.4) | C- (2.0) | C (2.2) |
| 2026-08-02 | C+ (2.7) | C- (2.0) | C- (2.0) | C (2.4) | C- (1.9) | C (2.2) |
| 2024-06-30 | C+ (2.6) | F (0.1) | D+ (1.7) | D- (0.8) | D (1.5) | D (1.3) |